Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.46 |
| ▸ | F2 | P00734 | 5/20 | 0.46 |
| ▸ | PLAU | P00749 | 5/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516872 | 0.91 | ELANE (0.43) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL29190579 | 0.91 | ELANE (0.41) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL16164146 | 0.90 | ELANE (0.45) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL16164144 | 0.90 | ELANE (0.45) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL30833809 | 0.83 | ELANE (0.41) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL3516297 | 0.82 | ELANE (0.35) | ELANE | |
| SCHEMBL15081365 | 0.82 | ELANE (0.43) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL16164313 | 0.81 | ELANE (0.50) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL16164311 | 0.81 | ELANE (0.50) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL15081358 | 0.80 | ELANE (0.45) | ELANEF2PLAUCTRB1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | ELANE 914/4885F2 2208/4885PLAU 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.